Phase II trial of oxaliplatin (OXA) and topotecan (TOP) as a first line treatment for the patients (pts) with advanced ovarian cancer (AOC): Preliminary results of a pilot study

Gorbounova, Vera; Topchieva, S. V.; Besova, N.

doi:10.1200/jco.2005.23.16_suppl.5116

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preliminary results of a phase II study demonstrated the adjuvant activity of the administration of oxaliplatin 80-100 mg/m 2 on day 1 followed by topotecan 1.5 mg/m 2 /day on days 2-4 every 21 days in 17 patients with advanced ovarian cancer (12 chemonaive and 5 platinum sensitive) with a treatment-free interval of more than 12 months (49) . The toxicity profile was acceptable.…”

Section: Oxaliplatin Plus Topotecanmentioning

confidence: 99%

Clinical application of oxaliplatin in epithelial ovarian cancer

Fu¹,

Kavanagh²,

Hu³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Platinum remains the most active drug class in ovarian cancer treatment; however, new single-agent and combination therapies are needed to improve the clinical outcome of ovarian cancer therapies. Oxaliplatin, a third-generation platinum derivative, has shown effective antitumor activity and a favorable toxicity profile in epithelial ovarian cancer. Preclinical evidence of the synergistic cytotoxic effect of oxaliplatin in combination with several other chemotherapeutic agents and clinical evidence of the absence of any dose-limiting hematologic toxicity associated with this agent have made oxaliplatin an attractive compound for combination agent therapy. This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment.

show abstract

Section: Oxaliplatin Plus Topotecanmentioning

confidence: 99%